Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a post-pandemic world, Pfizer and Moderna shares lost about 30% of their respective value over the past year. Yet, these struggling pharma companies are promising to turn the tide with their new long-term focus on oncology. Moreover, smaller companies like Mainz Biomed N.V. (NASDAQ:MYNZ) already broke ground when it comes to revolutionizing cancer treatment.
Pfizer might be down, but it is certainly not...
Login or create a forever free account to read this news
Sign up/Log in